更正：发现FLT3抑制剂LDD1937作为急性髓性白血病的抗白血病药物。
Correction: Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia.
作者信息
Lee Hyo Jeong, Lee Jungeun, Jeong Pyeonghwa, Choi Jungil, Baek Juhwa, Ahn Su Lin, Moon Yeongyu, Heo Jeong Doo, Choi Young Hee, Chin Young-Won, Kim Yong-Chul, Han Sun-Young
机构信息
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju, Republic of Korea.
School of Life Sciences,Gwangju Institute of Science and Technology, Gwangju, Republic of Korea.
出版信息
Oncotarget. 2018 Apr 13;9(28):20219. doi: 10.18632/oncotarget.25141.
Abstract
[This corrects the article DOI: 10.18632/oncotarget.23221.].
摘要
[本文更正了文章的数字对象标识符：10.18632/oncotarget.23221。]
相似文献
1
Correction: Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia.更正：发现FLT3抑制剂LDD1937作为急性髓性白血病的抗白血病药物。
Oncotarget. 2018 Apr 13;9(28):20219. doi: 10.18632/oncotarget.25141.
2
Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia.发现FLT3抑制剂LDD1937作为急性髓系白血病的抗白血病药物。
Oncotarget. 2017 Dec 14;9(1):924-936. doi: 10.18632/oncotarget.23221. eCollection 2018 Jan 2.
3
Correction: The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia.更正：高三尖杉酯碱与伊布替尼对FLT3-ITD突变型急性髓系白血病的联合作用
Oncotarget. 2019 Nov 12;10(61):6641-6642. doi: 10.18632/oncotarget.27310.
4
Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.更正：吉列替尼：一种用于急性髓系白血病的新型FLT3抑制剂。
Biomark Res. 2019 Oct 17;7:21. doi: 10.1186/s40364-019-0172-0. eCollection 2019.
5
Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia.联合抑制GLI和FLT3信号传导可对人类急性髓性白血病产生有效的抗白血病作用。
Oncotarget. 2017 Apr 25;8(17):29187-29201. doi: 10.18632/oncotarget.16304.
6
Correction: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.更正：抑制由肌醇需求酶1α（IRE1α）驱动的促生存途径是急性髓系白血病中一种有前景的治疗应用。
Oncotarget. 2017 Sep 8;8(38):64651. doi: 10.18632/oncotarget.20707.
7
Correction: Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6.更正：伴有t(4;12)(q12;p13)的急性髓系白血病：一种侵袭性疾病，常累及血小板衍生生长因子受体A（PDGFRA）和ETS变异体6（ETV6）
Oncotarget. 2018 Sep 28;9(76):34449. doi: 10.18632/oncotarget.26205.
8
Correction: Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.更正：基因表达谱分析在野生型FLT3急性髓系白血病中鉴定出FLT3突变样病例。
PLoS One. 2022 Sep 15;17(9):e0274984. doi: 10.1371/journal.pone.0274984. eCollection 2022.
9
Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents.新型基于噻吩并[2,3-d]嘧啶的FLT3抑制剂作为抗白血病药物的合成及生物学评价
Eur J Med Chem. 2014 Oct 6;85:399-407. doi: 10.1016/j.ejmech.2014.08.001. Epub 2014 Aug 1.
10
Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.更正：NKp30表达是用于中危急性髓系白血病患者分层的预后免疫生物标志物。
Oncotarget. 2019 Sep 10;10(52):5493. doi: 10.18632/oncotarget.27198.
引用本文的文献
1
Development of UHPLC-MS/MS Method for Indirubin-3'-Oxime Derivative as a Novel FLT3 Inhibitor and Pharmacokinetic Study in Rats.建立 UHPLC-MS/MS 法测定新型 FLT3 抑制剂吲达莫司汀衍生物在大鼠体内的药代动力学。
Molecules. 2020 Apr 27;25(9):2039. doi: 10.3390/molecules25092039.
Zotero 插件